Onychomycosis Severity Index (OSI): Scoring Toenail Fungus for Treatment Selection

The Onychomycosis Severity Index (OSI) is a validated clinical scoring tool that quantifies the extent of toenail fungal infection to guide treatment selection, predict treatment outcomes, and standardize clinical documentation. The OSI was developed because toenail onychomycosis ranges from minimal subungual involvement affecting less than 10% of the nail plate to total nail dystrophy with complete destruction — and the appropriate treatment differs substantially across this spectrum. A patient with OSI 1-5 (mild) has an excellent prognosis with topical antifungal monotherapy; a patient with OSI 20-35 (severe) requires systemic oral antifungal therapy with poor topical monotherapy outcomes. Additionally, the OSI quantifies nail matrix involvement, which is the single most important prognostic factor — matrix involvement (proximal subungual onychomycosis or white superficial onychomycosis with matrix extension) dramatically reduces cure rates for any treatment modality.

Onychomycosis Severity Index: Scoring Components

Component	Measure	Score	Clinical Significance
Area of nail plate involvement	Percentage of nail plate with onychomycosis: <10% = 1; 10-25% = 2; 26-50% = 3; 51-75% = 4; >75% = 5	1-5 points	Larger affected area requires longer systemic treatment and has lower cure rate; determines whether topical therapy is appropriate
Proximity to nail matrix	Distance from disease to nail matrix (proximal nail fold): >5mm = 0; 2-5mm = 1; <2mm = 2	0-2 points	Matrix-reaching infection dramatically reduces treatment success; matrix involvement means infected nail plate will continue growing from infected matrix cells; proximal nail fold involvement = worst prognosis
Subtype of onychomycosis	Distal lateral subungual onychomycosis (DLSO) = 1; white superficial (WSO) = 1; proximal subungual (PSO) = 1; total dystrophic (TDO) = 1; dermatophytoma (fungal mass) = 1	0-1 additional point per modifier present (added to base area score)	PSO and TDO indicate severe disease; PSO specifically indicates matrix involvement and immunocompromised state; dermatophytoma (compact yellow-white streak) reduces cure rate
FINAL OSI Score	Sum of area score (1-5) + proximity score (0-2) + subtype modifier (0-1); maximum = 8 — then multiply area score by proximity score = ranges from 0-35 in some formulations	Total: 1-35	Mild (1-5); Moderate (6-15); Severe (16-35)

OSI Score and Treatment Recommendations

OSI Score	Severity	Typical Clinical Appearance	Recommended Treatment	Cure Rate Expectation
1-5 (Mild)	Mild	Distal or lateral 10-50% nail involvement; white or yellow-brown discoloration; no matrix involvement; minimal nail thickening	Topical antifungal monotherapy: ciclopirox 8% lacquer daily x 48 weeks; efinaconazole 10% solution daily x 48 weeks; tavaborole 5% solution daily x 48 weeks; nail debridement at each visit accelerates response	Topical: 20-50% complete mycological cure at 52 weeks (lower but acceptable for mild disease avoiding systemic drug exposure)
6-15 (Moderate)	Moderate	50-75% nail involvement; significant subungual hyperkeratosis; nail thickening; approaching but not reaching matrix; or mild disease with proximal subungual component	Oral antifungal preferred: terbinafine 250mg/day x 12 weeks (dermatophyte); itraconazole 200mg/day x 12 weeks (dermatophyte + yeast); consider combination oral + topical; nail debridement monthly	Oral terbinafine: 50-70% mycological cure at 52 weeks for moderate disease
16-35 (Severe)	Severe	Total nail dystrophy; >75% involvement; matrix involvement; proximal subungual pattern; dermatophytoma present; multiple nails involved	Oral antifungal mandatory: terbinafine 250mg/day x 12 weeks first-line; itraconazole pulse therapy (400mg/day x 7 days/month x 3-4 months) if hepatic concern; combination oral + topical; consider laser (nd:YAG) adjunct; chemical or surgical avulsion in refractory cases; confirm diagnosis with culture before systemic therapy	Oral therapy: 35-55% complete cure; lower for severe; high recurrence rate (25-30% at 3 years); ongoing suppressive therapy may be indicated
Any score with matrix involvement	Any severity (matrix modifier)	Proximal subungual onychomycosis; white discoloration at lunula; fungus at or within nail matrix	Always requires oral antifungal — no topical therapy reaches matrix adequately; evaluate for immunodeficiency (HIV, diabetes, immunosuppression) as PSO pattern is associated with these conditions	Significantly lower than equivalent non-matrix-involving disease; relapse common

At Balance Foot & Ankle in Howell and Bloomfield Hills, onychomycosis severity is scored with the OSI at every initial evaluation — the score determines whether to prescribe topical efinaconazole alone, oral terbinafine, or combination therapy, and establishes a baseline for measuring treatment response at the 12-week and 52-week follow-up visits. Call (810) 206-1402.